Global VRE and MRSA Antibiotic Market Size, Share, Trends and Forecast 2022-2030

Description

Methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE) are specific, antibiotic-resistant bacteria that spread by contact and can cause serious infections. MRSA can be spread by touching articles that have been contaminated by the skin of an infected or colonized person, such as towels, sheets, and wound dressings; VRE can be transmitted by touching articles soiled by an infected person's feces. Both of these bacteria survive well on hands and for weeks on inanimate objects. Colonization occurs when bacteria are present on or in the body (i.e., nose, skin, rectum, moist areas of the body and the newborn's umbilicus) without causing illness.
An antibiotic is a type of antimicrobial substance active against bacteria. It is the most important type of antibacterial agent for fighting bacterial infections, and antibiotic medications are widely used in the treatment and prevention of such infections. They may either kill or inhibit the growth of bacteria.

Industry Insights

Due to the COVID-19 pandemic, the global VRE and MRSA Antibiotic market size is estimated to be worth US$ 4055.6 million in 2021 and is forecast to a readjusted size of US$ 5354.3 million by 2028 with a CAGR of 4.0% during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe VRE and MRSA Antibiotic market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe VRE and MRSA Antibiotic landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.

The market for is VRE and MRSA antibiotic market fragmented with players such as Pfizer, Lilly, Sanofi Aventis, Merck, Fresenius Kabi, Xellia Pharmaceuticals (Novo Holdings), Zhejiang Medicine, Zhejiang Hisun Pharmaceutical, North China Pharmaceutical. Among the companies, pfizer contributed 17% of the market, which is the biggest in 2020.In terms of product, linezolid is the largest segment, with a share over 38%. And in terms of application, the largest application is hospitals.

This report focuses on VRE and MRSA Antibiotic volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall VRE and MRSA Antibiotic market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and South Korea, etc.

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Post-covid-19 Outlook

The readers in the section will understand how the VRE and MRSA Antibiotic market scenario changed across the globe during the pandemic and post-pandemic. The study is done keeping in view the changes in aspects such as sales, demand and supply chain. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.

Segmental Outlook

Key segments including type and application have been elaborated in this report. The consultants at QY Research have studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows sales and revenue data by type, and application during the historical period (2017-2022) and forecast period (2023-2028).

Segment by Type

Vancomycin

Teicoplanin

Linezolid

Daptomycin

Others

Segment by Application

Hospitals

Clinics

Others

Regional Outlook

This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue and sales data of each region and country for the period 2017-2028. This information derived through comprehensive research will help the reader to get familiar with the potential value of the investment in a particular region.

North America

U.S.

Canada

Europe

Germany

France

U.K.

Italy

Russia

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Indonesia

Thailand

Malaysia

Philippines

Vietnam

Latin America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Competitive Scenario

In this section, the readers will gain an understanding of the key players competing. The experts at QY Research have studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:

Pfizer

Lilly

Sanofi Aventis

Merck

Fresenius Kabi

Xellia Pharmaceuticals (Novo Holdings)

Zhejiang Medicine

Zhejiang Hisun Pharmaceutical

North China Pharmaceutical

Korea United Pharm

TABLE OF CONTENT

1 VRE and MRSA Antibiotic Market Overview
1.1 Product Overview and Scope of VRE and MRSA Antibiotic

1.2 VRE and MRSA Antibiotic Segment by Type

1.2.1 Global VRE and MRSA Antibiotic Sales Growth Rate Comparison by Type (2022-2028)

1.2.2 Vancomycin

1.2.3 Teicoplanin

1.2.4 Linezolid

1.2.5 Daptomycin

1.2.6 Others

1.3 VRE and MRSA Antibiotic Segment by Application

1.3.1 Global VRE and MRSA Antibiotic Sales Comparison by Application: (2022-2028)

1.3.2 Hospitals

1.3.3 Clinics

1.3.4 Others

1.4 Global VRE and MRSA Antibiotic Market Size Estimates and Forecasts

1.4.1 Global VRE and MRSA Antibiotic Revenue 2017-2028

1.4.2 Global VRE and MRSA Antibiotic Sales 2017-2028

1.4.3 VRE and MRSA Antibiotic Market Size by Region: 2017 Versus 2021 Versus 2028

2 VRE and MRSA Antibiotic Market Competition by Manufacturers

2.1 Global VRE and MRSA Antibiotic Sales Market Share by Manufacturers (2017-2022)

2.2 Global VRE and MRSA Antibiotic Revenue Market Share by Manufacturers (2017-2022)

2.3 Global VRE and MRSA Antibiotic Average Price by Manufacturers (2017-2022)

2.4 Manufacturers VRE and MRSA Antibiotic Manufacturing Sites, Area Served, Product Type

2.5 VRE and MRSA Antibiotic Market Competitive Situation and Trends

2.5.1 VRE and MRSA Antibiotic Market Concentration Rate

2.5.2 The Global Top 5 and Top 10 Largest VRE and MRSA Antibiotic Players Market Share by Revenue

2.5.3 Global VRE and MRSA Antibiotic Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 VRE and MRSA Antibiotic Retrospective Market Scenario by Region

3.1 Global VRE and MRSA Antibiotic Retrospective Market Scenario in Sales by Region: 2017-2022

3.2 Global VRE and MRSA Antibiotic Retrospective Market Scenario in Revenue by Region: 2017-2022

3.3 North America VRE and MRSA Antibiotic Market Facts & Figures by Country

3.3.1 North America VRE and MRSA Antibiotic Sales by Country

3.3.2 North America VRE and MRSA Antibiotic Revenue by Country

3.3.3 U.S.

3.3.4 Canada

3.4 Europe VRE and MRSA Antibiotic Market Facts & Figures by Country

3.4.1 Europe VRE and MRSA Antibiotic Sales by Country

3.4.2 Europe VRE and MRSA Antibiotic Revenue by Country

3.4.3 Germany

3.4.4 France

3.4.5 U.K.

3.4.6 Italy

3.4.7 Russia

3.5 Asia Pacific VRE and MRSA Antibiotic Market Facts & Figures by Region

3.5.1 Asia Pacific VRE and MRSA Antibiotic Sales by Region

3.5.2 Asia Pacific VRE and MRSA Antibiotic Revenue by Region

3.5.3 China

3.5.4 Japan

3.5.5 South Korea

3.5.6 India

3.5.7 Australia

3.5.8 Taiwan

3.5.9 Indonesia

3.5.10 Thailand

3.5.11 Malaysia

3.5.12 Philippines

3.5.13 Vietnam

3.6 Latin America VRE and MRSA Antibiotic Market Facts & Figures by Country

3.6.1 Latin America VRE and MRSA Antibiotic Sales by Country

3.6.2 Latin America VRE and MRSA Antibiotic Revenue by Country

3.6.3 Mexico

3.6.4 Brazil

3.6.5 Argentina

3.7 Middle East and Africa VRE and MRSA Antibiotic Market Facts & Figures by Country

3.7.1 Middle East and Africa VRE and MRSA Antibiotic Sales by Country

3.7.2 Middle East and Africa VRE and MRSA Antibiotic Revenue by Country

3.7.3 Turkey

3.7.4 Saudi Arabia

3.7.5 UAE

4 Global VRE and MRSA Antibiotic Historic Market Analysis by Type

4.1 Global VRE and MRSA Antibiotic Sales Market Share by Type (2017-2022)

4.2 Global VRE and MRSA Antibiotic Revenue Market Share by Type (2017-2022)

4.3 Global VRE and MRSA Antibiotic Price by Type (2017-2022)

5 Global VRE and MRSA Antibiotic Historic Market Analysis by Application

5.1 Global VRE and MRSA Antibiotic Sales Market Share by Application (2017-2022)

5.2 Global VRE and MRSA Antibiotic Revenue Market Share by Application (2017-2022)

5.3 Global VRE and MRSA Antibiotic Price by Application (2017-2022)

6 Key Companies Profiled

6.1 Pfizer

6.1.1 Pfizer Corporation Information

6.1.2 Pfizer Description and Business Overview

6.1.3 Pfizer VRE and MRSA Antibiotic Sales, Revenue and Gross Margin (2017-2022)

6.1.4 Pfizer VRE and MRSA Antibiotic Product Portfolio

6.1.5 Pfizer Recent Developments/Updates

6.2 Lilly

6.2.1 Lilly Corporation Information

6.2.2 Lilly Description and Business Overview

6.2.3 Lilly VRE and MRSA Antibiotic Sales, Revenue and Gross Margin (2017-2022)

6.2.4 Lilly VRE and MRSA Antibiotic Product Portfolio

6.2.5 Lilly Recent Developments/Updates

6.3 Sanofi Aventis

6.3.1 Sanofi Aventis Corporation Information

6.3.2 Sanofi Aventis Description and Business Overview

6.3.3 Sanofi Aventis VRE and MRSA Antibiotic Sales, Revenue and Gross Margin (2017-2022)

6.3.4 Sanofi Aventis VRE and MRSA Antibiotic Product Portfolio

6.3.5 Sanofi Aventis Recent Developments/Updates

6.4 Merck

6.4.1 Merck Corporation Information

6.4.2 Merck Description and Business Overview

6.4.3 Merck VRE and MRSA Antibiotic Sales, Revenue and Gross Margin (2017-2022)

6.4.4 Merck VRE and MRSA Antibiotic Product Portfolio

6.4.5 Merck Recent Developments/Updates

6.5 Fresenius Kabi

6.5.1 Fresenius Kabi Corporation Information

6.5.2 Fresenius Kabi Description and Business Overview

6.5.3 Fresenius Kabi VRE and MRSA Antibiotic Sales, Revenue and Gross Margin (2017-2022)

6.5.4 Fresenius Kabi VRE and MRSA Antibiotic Product Portfolio

6.5.5 Fresenius Kabi Recent Developments/Updates

6.6 Xellia Pharmaceuticals (Novo Holdings)

6.6.1 Xellia Pharmaceuticals (Novo Holdings) Corporation Information

6.6.2 Xellia Pharmaceuticals (Novo Holdings) Description and Business Overview

6.6.3 Xellia Pharmaceuticals (Novo Holdings) VRE and MRSA Antibiotic Sales, Revenue and Gross Margin (2017-2022)

6.6.4 Xellia Pharmaceuticals (Novo Holdings) VRE and MRSA Antibiotic Product Portfolio

6.6.5 Xellia Pharmaceuticals (Novo Holdings) Recent Developments/Updates

6.7 Zhejiang Medicine

6.6.1 Zhejiang Medicine Corporation Information

6.6.2 Zhejiang Medicine Description and Business Overview

6.6.3 Zhejiang Medicine VRE and MRSA Antibiotic Sales, Revenue and Gross Margin (2017-2022)

6.4.4 Zhejiang Medicine VRE and MRSA Antibiotic Product Portfolio

6.7.5 Zhejiang Medicine Recent Developments/Updates

6.8 Zhejiang Hisun Pharmaceutical

6.8.1 Zhejiang Hisun Pharmaceutical Corporation Information

6.8.2 Zhejiang Hisun Pharmaceutical Description and Business Overview

6.8.3 Zhejiang Hisun Pharmaceutical VRE and MRSA Antibiotic Sales, Revenue and Gross Margin (2017-2022)

6.8.4 Zhejiang Hisun Pharmaceutical VRE and MRSA Antibiotic Product Portfolio

6.8.5 Zhejiang Hisun Pharmaceutical Recent Developments/Updates

6.9 North China Pharmaceutical

6.9.1 North China Pharmaceutical Corporation Information

6.9.2 North China Pharmaceutical Description and Business Overview

6.9.3 North China Pharmaceutical VRE and MRSA Antibiotic Sales, Revenue and Gross Margin (2017-2022)

6.9.4 North China Pharmaceutical VRE and MRSA Antibiotic Product Portfolio

6.9.5 North China Pharmaceutical Recent Developments/Updates

6.10 Korea United Pharm

6.10.1 Korea United Pharm Corporation Information

6.10.2 Korea United Pharm Description and Business Overview

6.10.3 Korea United Pharm VRE and MRSA Antibiotic Sales, Revenue and Gross Margin (2017-2022)

6.10.4 Korea United Pharm VRE and MRSA Antibiotic Product Portfolio

6.10.5 Korea United Pharm Recent Developments/Updates

7 VRE and MRSA Antibiotic Manufacturing Cost Analysis

7.1 VRE and MRSA Antibiotic Key Raw Materials Analysis

7.1.1 Key Raw Materials

7.1.2 Key Suppliers of Raw Materials

7.2 Proportion of Manufacturing Cost Structure

7.3 Manufacturing Process Analysis of VRE and MRSA Antibiotic

7.4 VRE and MRSA Antibiotic Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers

8.1 Marketing Channel

8.2 VRE and MRSA Antibiotic Distributors List

8.3 VRE and MRSA Antibiotic Customers

9 VRE and MRSA Antibiotic Market Dynamics

9.1 VRE and MRSA Antibiotic Industry Trends

9.2 VRE and MRSA Antibiotic Market Drivers

9.3 VRE and MRSA Antibiotic Market Challenges

9.4 VRE and MRSA Antibiotic Market Restraints

10 Global Market Forecast

10.1 VRE and MRSA Antibiotic Market Estimates and Projections by Type

10.1.1 Global Forecasted Sales of VRE and MRSA Antibiotic by Type (2023-2028)

10.1.2 Global Forecasted Revenue of VRE and MRSA Antibiotic by Type (2023-2028)

10.2 VRE and MRSA Antibiotic Market Estimates and Projections by Application

10.2.1 Global Forecasted Sales of VRE and MRSA Antibiotic by Application (2023-2028)

10.2.2 Global Forecasted Revenue of VRE and MRSA Antibiotic by Application (2023-2028)

10.3 VRE and MRSA Antibiotic Market Estimates and Projections by Region

10.3.1 Global Forecasted Sales of VRE and MRSA Antibiotic by Region (2023-2028)

10.3.2 Global Forecasted Revenue of VRE and MRSA Antibiotic by Region (2023-2028)

11 Research Finding and Conclusion

12 Methodology and Data Source

12.1 Methodology/Research Approach

12.1.1 Research Programs/Design

12.1.2 Market Size Estimation

12.1.3 Market Breakdown and Data Triangulation

12.2 Data Source

12.2.1 Secondary Sources

12.2.2 Primary Sources

12.3 Author List

12.4 Disclaimer

Choose License Type

Checkout Inquiry Sample